The position of SGLT2 inhibitors in current medicine

Czech version

Authors: Martin Prázný
Authors‘ workplace: 3. interní klinika VFN a 1. LF UK v Praze
Published in: Vnitř Lék 2020; 66(2): 82-88
Category: Main Topic

Kardiovaskulární onemocnění jsou u pacientů s diabetem 2. typu stále nejčastější příčinou úmrtnosti. V souvislosti s požadavky na průkaz kardiovaskulární bezpečnosti nových antidiabetik, která v posledních 20 letech významně rozšířila léčebné možnosti diabetu, přinesly některé prospektivní studie neočekávané výsledky.

Overview

Cardiovascular disease is still the most common cause of mortality in patients with type 2 diabetes. Some prospective studies have produced unexpected results in connection with the requirements for the demonstration of cardiovascular safety of new antidiabetics, which have significantly expanded the treatment options for diabetes over the past 20 years. Although these studies were statistically designed to exclude excessive cardiovascular risk in patients with type 2 diabetes, some drugs have shown not only cardiovascular safety but also significant cardioprotective and nephroprotective effects in these studies. For the first time, a reduction in cardiovascular and overall mortality was demonstrated for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME trial in patients at very high cardiovascular risk. We already know that a beneficial effect on the risk of heart failure, but also renal failure, is a class effect in gliflozins. The revolutionary benefits of SGLT2 inhibitors are now perceived not only by diabetologists, but also by cardiologists and nephrologists. In European Society of Cardiology clinical guidelines, gliflozins even endanger the still unshakable position of metformin as the first line of antidiabetic therapy in patients with very high cardiovascular risk. Their indication should be today considered in all patients with type 2 diabetes and atherosclerosis, cardiac and renal failure regardless of diabetes control because they can reduce cardiovascular risk, risk of hospitalizations for heart failure and preserve glomerular filtration rate.

Keywords:

SGLT2 inhibitors – type 2 diabetes – cardiovascular risk – heart failure – chronic kidney disease – glucuretics

Sources

1. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine, 1998; 15(7): 539–553.

2. World Health, O., Global Report on Diabetes. Global Report on Diabetes, 2016.

3. Nwaneri CH. Cooper DBJ. Mortality in type 2 diabetes mellitus: Magnitude of the evidence from a systematic review and meta -analysis. British Journal of Diabetes and Vascular Disease, 2013; 13(4): 192–207.

4. Cubbon RM, et al. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diabetes and Vascular Disease Research, 2013; 10(4): 330–336.

5. MacDonald MR, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure – An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. European Heart Journal, 2008; 29(11): 1377–1385.

6. Matsushita K, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. The Lancet, 2010; 375(9731): 2073–2081.

7. Reidy K, et al. Molecular mechanisms of Diabetic kidney disease. Journal of Clinical Investigation, 2014; 124(6): 2333–2340.

8. Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 2015; 373(22): 2117–2128.

9. Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine, 2017; 377(7): 644–657.

10. Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 2019; 380(4): 347–357.

11. Cannon CP, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS -CV). American Heart Journal, 2018; 206: 11–23.

12. Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. The Lancet Diabetes and Endocrinology, 2018; 6(9): 691–704.

13. Neal B, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS -R): A randomized, placebo -controlled trial. Diabetes, Obesity and Metabolism, 2017; 19(3): 387–393.

14. Neal B, et al. Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS -R trials. Diabetes, Obesity and Metabolism, 2017; 19(7): 926–935.

15. Kosiborod M, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose -lowering drugs: The CVD-REAL study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium- -Glucose Cotransporter-2 Inhibitors). Circulation, 2017; 136(3): 249–259.

16. Kosiborod M, et al. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose -Lowering Drugs: The CVD -REAL 2 Study. Journal of the American College of Cardiology, 2018; 71(23): 2628–2639.

17. Udell JA, et al. Cardiovascular outcomes and risks after initiation of a sodium glucose cotransporter 2 inhibitor: Results from the EASEL population -based cohort study (evidence for cardiovascular outcomes with sodium glucose cotransporter 2 inhibitors in the real world). Circulation, 2018; 137(14): 1450–1459.

18. Patorno E, et al. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care: A First Analysis from the EMPRISE Study. Circulation, 2019; 139(25): 2822–2830.

19. Jardine MJ, et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. American journal of nephrology, 2017; 46(6): 462–472.

20. McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med, 2019; 381(21): 1995–2008.

21. Abraham WT, et al. Rationale and design of the EMPERIAL -Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. European Journal of Heart Failure, 2019; 21(7): 932–942.

22. Herrington WG, et al. The potential for improving cardio -renal outcomes by sodium- -glucose co -transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA -KIDNEY study. Clinical Kidney Journal, 2018; 11(6): 749–761.

23. Davies MJ, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2018; 61(12): 2461–2498.

24. BuseJB, et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2020; 63(2): 221–228.

25. Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre -diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre -diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). European Heart Journal, 2019; 41(2): 255–323.